




# Prescriber's guide to once-daily dosing for adjunctive treatment in major depressive disorder (MDD)

## REXULTI® (brexpiprazole)—titration options for the adjunctive treatment of patients with MDD

Recommended target dose: 2 mg/day



- ▶ REXULTI is available in 2 mg tablets, as well as other dosage strengths
- ▶ Dosage increases should occur at weekly intervals based on the patient's clinical response and tolerability, and should be periodically reassessed to determine the continued need and appropriate dosage for treatment
- ▶ Optional titration to maximum dose of 3 mg/day
- ▶ Can be taken with or without food

## Dosage adjustments for REXULTI

- ▶ Dosage adjustments may be needed in patients with hepatic or renal impairment
- ▶ Administer half the dose of REXULTI when taken with strong CYP3A4 inhibitors or in patients who are known CYP2D6 poor metabolizers
- ▶ Administer a quarter of the dose with the concurrent use of both strong/moderate CYP2D6 inhibitors and strong/moderate CYP3A4 inhibitors. Likewise, administer a quarter of the dose in patients who are known CYP2D6 poor metabolizers taking strong/moderate CYP3A4 inhibitors
- ▶ Double the dose with strong CYP3A4 inducers over 1 to 2 weeks

## INDICATION and IMPORTANT SAFETY INFORMATION for REXULTI® (brexpiprazole)

### INDICATION

REXULTI is indicated for:

- Use as an adjunctive therapy to antidepressants in adults with major depressive disorder

### IMPORTANT SAFETY INFORMATION

#### WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

Antidepressants increase the risk of suicidal thoughts and behaviors in patients aged 24 years and younger. Monitor for clinical worsening and emergence of suicidal thoughts and behaviors. The safety and effectiveness of REXULTI have not been established in pediatric patients.

#### WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at increased risk of death. REXULTI is not approved for the treatment of patients with dementia-related psychosis.

## IMPORTANT SAFETY INFORMATION for REXULTI® (brexpiprazole) (continued)

**Contraindication:** In patients with known hypersensitivity reaction to brexpiprazole or any of its components. Reactions have included: rash, facial swelling, urticaria and anaphylaxis.

**Cerebrovascular Adverse Events, Including Stroke:** In clinical trials, elderly patients with dementia randomized to risperidone, aripiprazole, and olanzapine had a higher incidence of stroke and transient ischemic attack, including fatal stroke. REXULTI is not approved for the treatment of patients with dementia-related psychosis.

**Neuroleptic Malignant Syndrome (NMS):** NMS is a potentially fatal symptom complex reported in association with administration of antipsychotic drugs. Clinical signs of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability. Additional signs may include elevated creatinine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. Manage NMS with immediate discontinuation of REXULTI, intensive symptomatic treatment, and monitoring.

**Tardive Dyskinesia (TD):** Risk of TD, and the potential to become irreversible, are believed to increase with duration of treatment and total cumulative dose of antipsychotic drugs. TD can develop after a relatively brief treatment period, even at low doses, or after discontinuation of treatment. For chronic treatment, use the lowest dose and shortest duration of REXULTI needed to produce a clinical response. If signs and symptoms of TD appear, drug discontinuation should be considered.

**Metabolic Changes:** Atypical antipsychotic drugs have caused metabolic changes including:

- **Hyperglycemia/Diabetes Mellitus:** Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics. Assess fasting plasma glucose before or soon after initiation of antipsychotic medication, and monitor periodically during long-term treatment.
- **Dyslipidemia:** Atypical antipsychotics cause adverse alterations in lipids. Before or soon after initiation of antipsychotic medication, obtain a fasting lipid profile at baseline and monitor periodically during treatment.
- **Weight Gain:** Weight gain has been observed in patients treated with REXULTI. Monitor weight at baseline and frequently thereafter.

### **Pathological Gambling and Other Compulsive Behaviors:**

Intense urges, particularly for gambling, and the inability to control these urges have been reported while taking REXULTI. Other compulsive urges have been reported less frequently. Prescribers should ask patients or their caregivers about the development of new or intense compulsive urges. Consider dose reduction or stopping REXULTI if such urges develop.

**Leukopenia, Neutropenia, and Agranulocytosis:** Leukopenia and neutropenia have been reported with antipsychotics. Agranulocytosis (including fatal cases) has been reported with other agents in this class. Monitor complete blood count in

patients with pre-existing low white blood cell count (WBC)/ absolute neutrophil count or history of drug-induced leukopenia/neutropenia. Discontinue REXULTI at the first sign of a clinically significant decline in WBC and in severely neutropenic patients.

**Orthostatic Hypotension and Syncope:** Atypical antipsychotics cause orthostatic hypotension and syncope. Generally, the risk is greatest during initial dose titration and when increasing the dose. Monitor in patients vulnerable to hypotension, and those with cardiovascular and cerebrovascular diseases.

**Falls:** Antipsychotics may cause somnolence, postural hypotension, motor and sensory instability, which may lead to falls causing fractures or other injuries. For patients with diseases, conditions, or medications that could exacerbate these effects, complete fall risk assessments when initiating treatment and recurrently during therapy.

**Seizures:** REXULTI may cause seizures and should be used with caution in patients with a history of seizures or with conditions that lower the seizure threshold.

**Body Temperature Dysregulation:** Use REXULTI with caution in patients who may experience conditions that increase body temperature (e.g., strenuous exercise, extreme heat, dehydration, or concomitant use with anticholinergics).

**Dysphagia:** Esophageal dysmotility and aspiration have been associated with antipsychotics, including REXULTI, and should be used with caution in patients at risk for aspiration.

**Potential for Cognitive and Motor Impairment:** REXULTI has the potential to impair judgment, thinking, or motor skills. Patients should not drive or operate hazardous machinery until they are reasonably certain REXULTI does not affect them adversely.

**Concomitant Medication:** Dosage adjustments are recommended in patients who are known cytochrome P450 (CYP) 2D6 poor metabolizers and in patients taking concomitant CYP3A4 inhibitors or CYP2D6 inhibitors or strong CYP3A4 inducers.

**Most commonly observed adverse reactions:** In clinical trials, the most common adverse reactions were:

- **Major Depressive Disorder (MDD)** (adjunctive treatment to antidepressant therapy;  $\geq 5\%$  incidence and at least twice the rate of placebo for REXULTI vs. placebo): akathisia and weight increase

**Dystonia:** Symptoms of dystonia may occur in susceptible individuals during the first days of treatment and at low doses.

**Pregnancy:** Adequate and well-controlled studies to assess the risks of REXULTI during pregnancy have not been conducted. REXULTI should be used during pregnancy only if the benefit justifies the risk to the fetus.

**Lactation:** It is not known if REXULTI is excreted in human breast milk. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

To report SUSPECTED ADVERSE REACTIONS, contact Otsuka America Pharmaceutical, Inc. at 1-800-438-9927 or FDA at 1-800-FDA-1088 ([www.fda.gov/medwatch](http://www.fda.gov/medwatch)).

Please see [FULL PRESCRIBING INFORMATION](#), including **BOXED WARNING**.

